| Year |
Citation |
Score |
| 2023 |
Li Y, Xue M, Deng X, Dong L, Nguyen LXT, Ren L, Han L, Li C, Xue J, Zhao Z, Li W, Qing Y, Shen C, Tan B, Chen Z, ... ... Mulloy JC, et al. TET2-mediated mRNA demethylation regulates leukemia stem cell homing and self-renewal. Cell Stem Cell. 30: 1072-1090.e10. PMID 37541212 DOI: 10.1016/j.stem.2023.07.001 |
0.362 |
|
| 2023 |
Han L, Dong L, Leung K, Zhao Z, Li Y, Gao L, Chen Z, Xue J, Qing Y, Li W, Pokharel SP, Gao M, Chen M, Shen C, Tan B, ... ... Mulloy JC, et al. METTL16 drives leukemogenesis and leukemia stem cell self-renewal by reprogramming BCAA metabolism. Cell Stem Cell. 30: 52-68.e13. PMID 36608679 DOI: 10.1016/j.stem.2022.12.006 |
0.406 |
|
| 2022 |
Weng H, Huang F, Yu Z, Chen Z, Prince E, Kang Y, Zhou K, Li W, Hu J, Fu C, Aziz T, Li H, Li J, Yang Y, Han L, ... ... Mulloy JC, et al. The mA reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia. Cancer Cell. PMID 36306790 DOI: 10.1016/j.ccell.2022.10.004 |
0.326 |
|
| 2022 |
Tirtakusuma R, Szoltysek K, Milne P, Grinev V, Ptasinska A, Chin PS, Meyer C, Nakjang S, Hehir-Kwa JY, Williamson D, Cauchy P, Keane P, Assi SA, Ashtiani M, Kellaway SG, ... ... Mulloy JC, et al. Epigenetic regulator genes direct lineage switching in MLL/AF4 leukaemia. Blood. PMID 35839448 DOI: 10.1182/blood.2021015036 |
0.311 |
|
| 2022 |
Barreyro L, Sampson AM, Ishikawa C, Hueneman KM, Choi K, Pujato MA, Chutipongtanate S, Wyder M, Haffey WD, O'Brien E, Wunderlich M, Ramesh V, Kolb EM, Meydan C, Neelamraju Y, ... ... Mulloy JC, et al. Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia. Science Translational Medicine. 14: eabb7695. PMID 35263148 DOI: 10.1126/scitranslmed.abb7695 |
0.312 |
|
| 2021 |
Fishman H, Madiwale S, Geron I, Bari V, Van Loocke W, Kirschenbaum Y, Ganmore I, Kugler E, Rein-Gil A, Friedlander G, Schiby G, Birger Y, Strehl S, Soulier J, Knoechel B, ... ... Mulloy JC, et al. ETV6-NCOA2 fusion induces T/Myeloid mixed-phenotype leukemia by transformation of non-thymic hematopoietic progenitors. Blood. PMID 34624096 DOI: 10.1182/blood.2020010405 |
0.405 |
|
| 2021 |
Wunderlich M, Manning N, Sexton C, O'Brien E, Byerly L, Stillwell C, Perentesis JP, Mulloy JC, Mizukawa B. PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of Relapsed Pediatric B-Cell Acute Lymphoblastic Leukemia. Frontiers in Oncology. 11: 642466. PMID 33928030 DOI: 10.3389/fonc.2021.642466 |
0.347 |
|
| 2020 |
Su R, Dong L, Li Y, Gao M, Han L, Wunderlich M, Deng X, Li H, Huang Y, Gao L, Li C, Zhao Z, Robinson S, Tan B, Qing Y, ... ... Mulloy JC, et al. Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. Cancer Cell. PMID 32531268 DOI: 10.1016/J.Ccell.2020.04.017 |
0.404 |
|
| 2020 |
Hinge A, He J, Bartram J, Javier J, Xu J, Fjellman E, Sesaki H, Li T, Yu J, Wunderlich M, Mulloy J, Kofron M, Salomonis N, Grimes HL, Filippi MD. Asymmetrically Segregated Mitochondria Provide Cellular Memory of Hematopoietic Stem Cell Replicative History and Drive HSC Attrition. Cell Stem Cell. PMID 32059807 DOI: 10.1016/J.Stem.2020.01.016 |
0.344 |
|
| 2020 |
Wunderlich M, Manning N, O'Brien E, Sexton C, Byerly L, Perentesis JP, Mizukawa B, Mulloy JC. Abstract 5412: Xenograft based detection of rare leukemic clones in minimal residual disease negative diagnostic specimens from pediatric patients Cancer Research. 80: 5412-5412. DOI: 10.1158/1538-7445.Am2020-5412 |
0.385 |
|
| 2019 |
Khodoun MV, Morris SC, Angerman E, Potter C, Schuman R, Wunderlich M, Maciag JJ, Sullivan Locker KC, Mulloy JC, Herr AB, Finkelman FD. Rapid desensitization of humanized mice with anti-human FcRI monoclonal antibodies. The Journal of Allergy and Clinical Immunology. PMID 31836406 DOI: 10.1016/J.Jaci.2019.12.003 |
0.356 |
|
| 2019 |
Rodriguez S, Abundis C, Boccalatte F, Mehrotra P, Chiang MY, Yui MA, Wang L, Zhang H, Zollman A, Bonfim-Silva R, Kloetgen A, Palmer J, Sandusky G, Wunderlich M, Kaplan MH, ... Mulloy JC, et al. Therapeutic targeting of the E3 ubiquitin ligase SKP2 in T-ALL. Leukemia. PMID 31772299 DOI: 10.1038/S41375-019-0653-Z |
0.433 |
|
| 2019 |
Wunderlich M, Manning N, Sexton C, Sabulski A, Byerly L, O'Brien E, Perentesis JP, Mizukawa B, Mulloy JC. Improved chemotherapy modeling with RAG-based immune deficient mice. Plos One. 14: e0225532. PMID 31747424 DOI: 10.1371/Journal.Pone.0225532 |
0.408 |
|
| 2019 |
Melgar K, Walker MM, Jones LM, Bolanos LC, Hueneman K, Wunderlich M, Jiang JK, Wilson KM, Zhang X, Sutter P, Wang A, Xu X, Choi K, Tawa G, Lorimer D, ... ... Mulloy JC, et al. Overcoming adaptive therapy resistance in AML by targeting immune response pathways. Science Translational Medicine. 11. PMID 31484791 DOI: 10.1126/scitranslmed.aaw8828 |
0.369 |
|
| 2019 |
Huang Y, Su R, Sheng Y, Dong L, Dong Z, Xu H, Ni T, Zhang ZS, Zhang T, Li C, Han L, Zhu Z, Lian F, Wei J, Deng Q, ... ... Mulloy JC, et al. Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia. Cancer Cell. 35: 677-691.e10. PMID 30991027 DOI: 10.1016/J.Ccell.2019.03.006 |
0.511 |
|
| 2019 |
Goyama S, Schibler J, Mulloy JC. Alternative translation initiation generates the N-terminal truncated form of RUNX1 that retains hematopoietic activity. Experimental Hematology. PMID 30690039 DOI: 10.1016/J.Exphem.2019.01.008 |
0.388 |
|
| 2019 |
Wunderlich M, Chen J, O'Brien E, Manning N, Sexton C, Byerly L, Perentesis JP, Mizukawa B, Mulloy JC. Global Gene Expression and Mutation Signatures Are Preserved in PDX Models of Pediatric AML and Aid Discovery of Targeted Therapy for Cases with CBFA2T3/GLIS2 Rearrangement Blood. 134: 3766-3766. DOI: 10.1182/Blood-2019-129225 |
0.407 |
|
| 2019 |
Su R, Dong L, Li Y, Han L, Gao M, Wunderlich M, Deng X, Li H, Gao L, Li C, Robison S, Tan B, Qing Y, Qin X, Prince E, ... ... Mulloy JC, et al. Effective Novel Fto Inhibitors Show Potent Anti-Cancer Efficacy and Suppress Drug Resistance Blood. 134: 233-233. DOI: 10.1182/Blood-2019-124535 |
0.454 |
|
| 2018 |
Wunderlich M, Chou FS, Sexton C, Presicce P, Chougnet CA, Aliberti J, Mulloy JC. Improved multilineage human hematopoietic reconstitution and function in NSGS mice. Plos One. 13: e0209034. PMID 30540841 DOI: 10.1371/Journal.Pone.0209034 |
0.726 |
|
| 2018 |
Barve A, Casson L, Krem M, Wunderlich M, Mulloy JC, Beverly LJ. Comparative utility of NRG and NRGS mice for the study of normal hematopoiesis, leukemogenesis and therapeutic response. Experimental Hematology. PMID 30125602 DOI: 10.1016/J.Exphem.2018.08.004 |
0.433 |
|
| 2018 |
Mizukawa B, O'Brien E, Mulloy JC, Zheng Y. Cell Polarity and Division Symmetry Analyses in Transformed Blood Cells. Methods in Molecular Biology (Clifton, N.J.). 1821: 257-266. PMID 30062418 DOI: 10.1007/978-1-4939-8612-5_18 |
0.459 |
|
| 2018 |
Du W, Liu W, Mizukawa B, Shang X, Sipple J, Wunderlich M, Geiger H, Davies S, Mulloy J, Pang Q, Zheng Y. A non-myeloablative conditioning approach for long-term engraftment of human and mouse hematopoietic stem cells. Leukemia. PMID 29959415 DOI: 10.1038/S41375-018-0200-3 |
0.382 |
|
| 2018 |
Gracia-Maldonado G, Clark J, Pierre P, Mulloy JC, Kumar AR. The Role of LAMP5 in Innate Immune Signaling Is Critical for the Survival of MLL Leukemias Blood. 132: 3900-3900. DOI: 10.1182/Blood-2018-99-120190 |
0.494 |
|
| 2018 |
Rodriguez-Rodriguez S, Wang L, Zhang H, Mehrotra P, Zollman A, Kaplan M, Sandusky G, Chiang M, Mulloy J, Wunderlich M, Palmer J, Yui M, Cardoso A, Carlesso N. Loss of the E3 Ubiquitin Ligase SKP2 Limits De Oncogenic Potential of Notch in T-Cell Lymphoblastic Leukemia Experimental Hematology. 64: S98. DOI: 10.1016/J.Exphem.2018.06.133 |
0.364 |
|
| 2017 |
Eriksson M, Peña-Martínez P, Ramakrishnan R, Chapellier M, Högberg C, Glowacki G, Orsmark-Pietras C, Velasco-Hernández T, Lazarević VL, Juliusson G, Cammenga J, Mulloy JC, Richter J, Fioretos T, Ebert BL, et al. Agonistic targeting of TLR1/TLR2 induces p38 MAPK-dependent apoptosis and NFκB-dependent differentiation of AML cells. Blood Advances. 1: 2046-2057. PMID 29296851 DOI: 10.1182/Bloodadvances.2017006148 |
0.478 |
|
| 2017 |
Weng H, Huang H, Wu H, Qin X, Zhao BS, Dong L, Shi H, Skibbe J, Shen C, Hu C, Sheng Y, Wang Y, Wunderlich M, Zhang B, Dore LC, ... ... Mulloy JC, et al. METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m6A Modification. Cell Stem Cell. PMID 29290617 DOI: 10.1016/J.Stem.2017.11.016 |
0.5 |
|
| 2017 |
Su R, Dong L, Li C, Nachtergaele S, Wunderlich M, Qing Y, Deng X, Wang Y, Weng X, Hu C, Yu M, Skibbe J, Dai Q, Zou D, Wu T, ... ... Mulloy JC, et al. R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling. Cell. PMID 29249359 DOI: 10.1016/J.Cell.2017.11.031 |
0.352 |
|
| 2017 |
Jiang X, Hu C, Ferchen K, Nie J, Cui X, Chen CH, Cheng L, Zuo Z, Seibel W, He C, Tang Y, Skibbe JR, Wunderlich M, Reinhold WC, Dong L, ... ... Mulloy J, et al. Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia. Nature Communications. 8: 2099. PMID 29235481 DOI: 10.1038/S41467-017-02290-W |
0.462 |
|
| 2017 |
Mizukawa B, O'Brien E, Moreira DC, Wunderlich M, Hochstetler CL, Duan X, Liu W, Orr E, Grimes HL, Mulloy JC, Zheng Y. Cell polarity determinant CDC42 controls division symmetry to block leukemia cell differentiation. Blood. PMID 28778865 DOI: 10.1182/Blood-2016-12-758458 |
0.539 |
|
| 2017 |
Lin S, Ptasinska A, Chen X, Shrestha M, Assi SA, Chin PS, Imperato MR, Aronow B, Zhang J, Weirauch MT, Bonifer C, Mulloy JC. A FOXO1-induced oncogenic network defines the AML1-ETO pre-leukemic program. Blood. PMID 28710059 DOI: 10.1182/Blood-2016-11-750976 |
0.519 |
|
| 2017 |
Lin S, Luo RT, Shrestha M, Thirman MJ, Mulloy JC. The full transforming capacity of MLL-Af4 is interlinked with lymphoid lineage commitment. Blood. PMID 28637661 DOI: 10.1182/Blood-2017-04-777185 |
0.485 |
|
| 2017 |
Bertaux-Skeirik N, Wunderlich M, Teal E, Chakrabarti J, Biesiada J, Mahe M, Sundaram N, Gabre J, Hawkins J, Gao J, Engevik AC, Yang L, Wang J, Goldenring JR, Qualls JE, ... ... Mulloy JC, et al. CD44 variant isoform 9 emerges in response to injury and contributes to the regeneration of the gastric epithelium. The Journal of Pathology. PMID 28497484 DOI: 10.1002/Path.4918 |
0.351 |
|
| 2017 |
Kesarwani M, Kincaid Z, Gomaa A, Huber E, Rohrabaugh S, Siddiqui Z, Bouso MF, Latif T, Xu M, Komurov K, Mulloy JC, Cancelas JA, Grimes HL, Azam M. Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia. Nature Medicine. PMID 28319094 DOI: 10.1038/Nm.4310 |
0.409 |
|
| 2017 |
Lin S, Mulloy JC, Goyama S. RUNX1-ETO Leukemia. Advances in Experimental Medicine and Biology. 962: 151-173. PMID 28299657 DOI: 10.1007/978-981-10-3233-2_11 |
0.47 |
|
| 2017 |
Chen X, Clark J, Wunderlich M, Fan C, Davis A, Chen S, Guan JL, Mulloy JC, Kumar A, Zheng Y. Autophagy is dispensable for Kmt2a/Mll-Mllt3/Af9 AML maintenance and anti-leukemic effect of chloroquine. Autophagy. 1-12. PMID 28282266 DOI: 10.1080/15548627.2017.1287652 |
0.464 |
|
| 2017 |
Wunderlich M, Manning N, Sexton C, John PP, Mizukawa B, Mulloy JC. PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of B-Cell Acute Lymphoblastic Leukemia Blood. 130: 1318-1318. DOI: 10.1182/Blood.V130.Suppl_1.1318.1318 |
0.328 |
|
| 2017 |
Holokai LL, Bertaux-Skeirik N, Chakrabarti J, Wunderlich M, Chang J, Teal EL, Hawkins J, Sundaram N, Mahe MM, Helmrath M, Ahmad S, Mulloy JC, Zavros Y. Human-Derived Gastric Cancer Organoids Secrete Tumor Antigen that Activates Dendritic Cells and Subsequent Expression of PD-1 and CTLA-4 on Cytotoxic T Lymphocytes Gastroenterology. 152: S57. DOI: 10.1016/S0016-5085(17)30547-4 |
0.324 |
|
| 2016 |
Lin S, Luo RT, Ptasinska A, Kerry J, Assi SA, Wunderlich M, Imamura T, Kaberlein JJ, Rayes A, Althoff MJ, Anastasi J, O'Brien MM, Meetei AR, Milne TA, Bonifer C, ... Mulloy JC, et al. Instructive Role of MLL-Fusion Proteins Revealed by a Model of t(4;11) Pro-B Acute Lymphoblastic Leukemia. Cancer Cell. 30: 737-749. PMID 27846391 DOI: 10.1016/J.Ccell.2016.10.008 |
0.438 |
|
| 2016 |
Goyama S, Shrestha M, Schibler J, Rosenfeldt L, Miller W, O'Brien E, Mizukawa B, Kitamura T, Palumbo JS, Mulloy JC. Protease-activated receptor-1 inhibits proliferation but enhances leukemia stem cell activity in acute myeloid leukemia. Oncogene. PMID 27819671 DOI: 10.1038/Onc.2016.416 |
0.534 |
|
| 2016 |
Wunderlich M, Mulloy JC. MISTRG extends PDX modeling to favorable AMLs. Blood. 128: 2111-2112. PMID 27789435 DOI: 10.1182/Blood-2016-09-738757 |
0.349 |
|
| 2016 |
Wunderlich M, Stockman C, Devarajan M, Ravishankar N, Sexton C, Kumar AR, Mizukawa B, Mulloy JC. A xenograft model of macrophage activation syndrome amenable to anti-CD33 and anti-IL-6R treatment. Jci Insight. 1: e88181. PMID 27699249 DOI: 10.1172/Jci.Insight.88181 |
0.438 |
|
| 2016 |
Lin S, Wei J, Wunderlich M, Chou FS, Mulloy JC. Immortalization of human AE pre-leukemia cells by hTERT allows leukemic transformation. Oncotarget. PMID 27509060 DOI: 10.18632/Oncotarget.11093 |
0.753 |
|
| 2016 |
Link KA, Lin S, Shrestha M, Bowman M, Wunderlich M, Bloomfield CD, Huang G, Mulloy JC. Supraphysiologic levels of the AML1-ETO isoform AE9a are essential for transformation. Proceedings of the National Academy of Sciences of the United States of America. PMID 27457952 DOI: 10.1073/Pnas.1524225113 |
0.491 |
|
| 2016 |
Tran NT, Su H, Khodadadi-Jamayran A, Lin S, Zhang L, Zhou D, Pawlik KM, Townes TM, Chen Y, Mulloy JC, Zhao X. The AS-RBM15 lncRNA enhances RBM15 protein translation during megakaryocyte differentiation. Embo Reports. PMID 27118388 DOI: 10.15252/Embr.201541970 |
0.35 |
|
| 2016 |
Goyama S, Shikata S, Hayashi Y, Izawa Y, Schibler J, Iwamura H, Saito M, Kofuji S, Sumita K, Sasaki AT, Mulloy JC, Kitamura T. Inhibition of Impdh As an Effective Treatment for MLL-Fusion Leukemia Blood. 128: 750-750. DOI: 10.1182/Blood.V128.22.750.750 |
0.536 |
|
| 2016 |
Lin S, Ptasinska A, Assi SA, Kerry J, Meetei RA, Luo RT, Thirman MJ, Milne T, Bonifer C, Mulloy JC. The Transcriptome Heterogeneity of MLL-Fusion ALL Is Driven By Fusion Partners Via Distinct Chromatin Binding Blood. 128: 576-576. DOI: 10.1182/Blood.V128.22.576.576 |
0.416 |
|
| 2016 |
Cai X, Hayashi Y, Wunderlich M, Speck NA, Mulloy JC, Huang G, Zheng Y. Loss of Function RUNX1 Mutations Restrict Protein Biosynthesis during Pre-Leukemia and MDS Transition but Not after Leukemic Transformation Blood. 128: 3860-3860. DOI: 10.1182/Blood.V128.22.3860.3860 |
0.466 |
|
| 2016 |
Wunderlich M, Stockman C, Devarajan M, Ravishankar N, Sexton C, Kumar AR, Mizukawa B, Mulloy JC. A Xenograft Model of Lymphocyte-Independent, Effector-Driven Macrophage Activation SyndRome Amenable to Anti-CD33 and Anti-IL-6R Treatment Blood. 128: 3684-3684. DOI: 10.1182/Blood.V128.22.3684.3684 |
0.454 |
|
| 2016 |
Melgar K, Walker M, Jiang J, Wison K, Choi K, Mulloy JC, Thomas CJ, Starczynowski DT. Molecular Analysis and In Vivo Efficacy Studies on a Novel Chemical-Series of FLT3 Inhibitors in Human FLT3-ITD AML Blood. 128: 36-36. DOI: 10.1182/Blood.V128.22.36.36 |
0.448 |
|
| 2016 |
Goyama S, Shrestha M, Schibler J, Rosenfeldt L, Miller W, O'Brien E, Mizukawa B, Kitamura T, Palumbo JS, Mulloy JC. Protease-Activated Receptor 1 (PAR-1) Inhibits Proliferation but Enhances Leukemia Stem Cell Activity in Acute Myeloid Leukemia Blood. 128: 2730-2730. DOI: 10.1182/Blood.V128.22.2730.2730 |
0.562 |
|
| 2016 |
Gracia-Maldonado G, Clark J, Mulloy JC, Kumar AR. LAMP5 - a Novel Target of MLL-Fusion Proteins Is Required for the Propagation of Leukemia Blood. 128: 1512-1512. DOI: 10.1182/Blood.V128.22.1512.1512 |
0.567 |
|
| 2016 |
Lin S, Luo RT, Wunderlich M, Kaberlein JJ, Rayes A, Anastasi J, O'Brien MM, Mulloy JC, Thirman MJ. Abstract PR01: A novel MLL-AF4 in vivo model phenocopies t(4;11) pro-B ALL and reveals a lymphoid lineage bias of the fusion protein in human cells Cancer Research. 76. DOI: 10.1158/1538-7445.Pedca15-Pr01 |
0.504 |
|
| 2015 |
Benito JM, Godfrey L, Kojima K, Hogdal L, Wunderlich M, Geng H, Marzo I, Harutyunyan KG, Golfman L, North P, Kerry J, Ballabio E, Chonghaile TN, Gonzalo O, Qiu Y, ... ... Mulloy JC, et al. MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. Cell Reports. 13: 2715-27. PMID 26711339 DOI: 10.1016/J.Celrep.2015.12.003 |
0.454 |
|
| 2015 |
Goyama S, Schibler J, Gasilina A, Shrestha M, Lin S, Link KA, Chen J, Whitman SP, Bloomfield CD, Nicolet D, Assi S, Ptasinska A, Heidenreich O, Bonifer C, Kitamura T, ... ... Mulloy JC, et al. UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO. Leukemia. PMID 26449661 DOI: 10.1038/Leu.2015.275 |
0.539 |
|
| 2015 |
Thowfeik FS, Abdul Salam SF, Wunderlich M, Wyder M, Greis KD, Kadekaro AL, Mulloy JC, Merino EJ. A ROS-activatable agent elicits homologous recombination DNA repair and synergizes with pathway compounds. Chembiochem : a European Journal of Chemical Biology. PMID 26419938 DOI: 10.1002/Cbic.201500304 |
0.452 |
|
| 2015 |
Glait-Santar C, Desmond R, Feng X, Bat T, Chen J, Heuston E, Mizukawa B, Mulloy JC, Bodine DM, Larochelle A, Dunbar CE. Functional Niche Competition Between Normal Hematopoietic Stem and Progenitor Cells and Myeloid Leukemia Cells. Stem Cells (Dayton, Ohio). PMID 26388434 DOI: 10.1002/Stem.2208 |
0.489 |
|
| 2015 |
Ågerstam H, Karlsson C, Hansen N, Sandén C, Askmyr M, von Palffy S, Högberg C, Rissler M, Wunderlich M, Juliusson G, Richter J, Sjöström K, Bhatia R, Mulloy JC, Järås M, et al. Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America. 112: 10786-91. PMID 26261316 DOI: 10.1073/Pnas.1422749112 |
0.462 |
|
| 2015 |
Goyama S, Wunderlich M, Mulloy JC. Xenograft models for normal and malignant stem cells. Blood. 125: 2630-40. PMID 25762176 DOI: 10.1182/Blood-2014-11-570218 |
0.427 |
|
| 2015 |
Roychoudhury J, Clark JP, Gracia-Maldonado G, Unnisa Z, Wunderlich M, Link KA, Dasgupta N, Aronow B, Huang G, Mulloy JC, Kumar AR. MEIS1 regulates an HLF-oxidative stress axis in MLL-fusion gene leukemia. Blood. 125: 2544-52. PMID 25740828 DOI: 10.1182/Blood-2014-09-599258 |
0.424 |
|
| 2015 |
Goyama S, Huang G, Kurokawa M, Mulloy JC. Posttranslational modifications of RUNX1 as potential anticancer targets. Oncogene. 34: 3483-92. PMID 25263451 DOI: 10.1038/Onc.2014.305 |
0.349 |
|
| 2015 |
Itskovich SS, Clark J, Mulloy JC, Disney MD, Kumar AR. MBNL1 As a New Therapeutic Target in MLL-Fusion Gene Leukemia Blood. 126: 462-462. DOI: 10.1182/Blood.V126.23.462.462 |
0.534 |
|
| 2015 |
Melgar K, Walker M, Jiang J, Wilson K, Mulloy JC, Thomas CJ, Starczynowski DT. Novel Small Molecule FLT3 Inhibitors for the Treatment of FLT3-ITD AML Blood. 126: 3690-3690. DOI: 10.1182/Blood.V126.23.3690.3690 |
0.406 |
|
| 2015 |
Lin S, Luo RT, Wunderlich M, Kaberlein JJ, Rayes A, Anastasi J, O'Brien MM, Mulloy JC, Thirman MJ. Lymphoid Lineage Preference of MLL-AF4 Is Revealed in a Species-Specific Model Blood. 126: 2454-2454. DOI: 10.1182/Blood.V126.23.2454.2454 |
0.49 |
|
| 2014 |
Vadukoot AK, AbdulSalam SF, Wunderlich M, Pullen ED, Landero-Figueroa J, Mulloy JC, Merino EJ. Design of a hydrogen peroxide-activatable agent that specifically targets cancer cells. Bioorganic & Medicinal Chemistry. 22: 6885-92. PMID 25464887 DOI: 10.1016/J.Bmc.2014.10.029 |
0.388 |
|
| 2014 |
Kong G, Wunderlich M, Yang D, Ranheim EA, Young KH, Wang J, Chang YI, Du J, Liu Y, Tey SR, Zhang X, Juckett M, Mattison R, Damnernsawad A, Zhang J, ... Mulloy JC, et al. Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm. The Journal of Clinical Investigation. 124: 2762-73. PMID 24812670 DOI: 10.1172/Jci74182 |
0.526 |
|
| 2014 |
Wunderlich M, Brooks RA, Panchal R, Rhyasen GW, Danet-Desnoyers G, Mulloy JC. OKT3 prevents xenogeneic GVHD and allows reliable xenograft initiation from unfractionated human hematopoietic tissues. Blood. 123: e134-44. PMID 24778156 DOI: 10.1182/Blood-2014-02-556340 |
0.495 |
|
| 2014 |
Zhao X, Chen A, Yan X, Zhang Y, He F, Hayashi Y, Dong Y, Rao Y, Li B, Conway RM, Maiques-Diaz A, Elf SE, Huang N, Zuber J, Xiao Z, ... ... Mulloy JC, et al. Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal. Blood. 123: 1729-38. PMID 24449215 DOI: 10.1182/Blood-2013-03-489575 |
0.488 |
|
| 2014 |
Velu CS, Chaubey A, Phelan JD, Horman SR, Wunderlich M, Guzman ML, Jegga AG, Zeleznik-Le NJ, Chen J, Mulloy JC, Cancelas JA, Jordan CT, Aronow BJ, Marcucci G, Bhat B, et al. Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity. The Journal of Clinical Investigation. 124: 222-36. PMID 24334453 DOI: 10.1172/Jci66005 |
0.443 |
|
| 2014 |
Rhyasen GW, Wunderlich M, Tohyama K, Garcia-Manero G, Mulloy JC, Starczynowski DT. An MDS xenograft model utilizing a patient-derived cell line Leukemia. 28: 1142-1145. PMID 24326684 DOI: 10.1038/Leu.2013.372 |
0.5 |
|
| 2014 |
Lin S, Zhang J, Mulloy JC. Tumor Suppressor FOXO1 Serves As a Critical Oncogenic Mediator in AML1-ETO Leukemia Blood. 124: 264-264. DOI: 10.1182/Blood.V124.21.264.264 |
0.561 |
|
| 2014 |
Yan X, Hayashi Y, Zhao X, Chen A, Zhang Y, He F, Dong Y, Rao Y, Li B, Conway R, Maiques-Díaz A, Huang N, Elf SE, Zuber J, Xiao Z, ... ... Mulloy JC, et al. RUNX1/CBFβ Dosage Is Critical for MLL Leukemias Development Blood. 124: 2187-2187. DOI: 10.1182/Blood.V124.21.2187.2187 |
0.531 |
|
| 2014 |
Kong G, Mark W, Yang D, Ranheim EA, Young KH, Wang J, Chang Y, Du J, Liu Y, Tey SR, Zhang X, Juckett M, Mattison R, Damnernsawad A, Zhang J, ... Mulloy JC, et al. Abstract B22: Combined MEK and JAK inhibition rescues mutant hematopoietic stem cell function and provides long-term survival in NrasG12D/G12D mice Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Rasonc14-B22 |
0.509 |
|
| 2014 |
Velu CS, Chaubey A, Phelan JD, Meyer S, Horman SR, Wunderlich M, Guzman ML, Jegga AG, Zeleznik-Le NJ, Chen J, Mulloy JC, Cancelas JA, Jordan CT, Aronow BJ, Marcucci G, et al. Abstract 979: microRNA-mediated leukemia-initiating cell activity Cancer Research. 74: 979-979. DOI: 10.1158/1538-7445.Am2014-979 |
0.425 |
|
| 2014 |
Goyama S, Schibler J, Gasilina A, Shrestha M, Lin S, Link K, Nassar N, Mulloy JC. CBL restricts myeloid proliferation of human AML1-ETO preleukemia cells Experimental Hematology. 42: S36. DOI: 10.1016/J.Exphem.2014.07.129 |
0.562 |
|
| 2013 |
Mulloy JC. A new inducible model for t(8;21) AML. Embo Molecular Medicine. 5: 1795-7. PMID 24186472 DOI: 10.1002/Emmm.201303483 |
0.375 |
|
| 2013 |
Goyama S, Mulloy JC. NF-κB: a coordinator for epigenetic regulation by MLL. Cancer Cell. 24: 401-2. PMID 24135275 DOI: 10.1016/J.Ccr.2013.09.016 |
0.351 |
|
| 2013 |
Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, ... ... Mulloy JC, et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. The Journal of Clinical Investigation. 123: 4144-57. PMID 23999433 DOI: 10.1172/Jci68951 |
0.4 |
|
| 2013 |
Goyama S, Schibler J, Cunningham L, Zhang Y, Rao Y, Nishimoto N, Nakagawa M, Olsson A, Wunderlich M, Link KA, Mizukawa B, Grimes HL, Kurokawa M, Liu PP, Huang G, ... Mulloy JC, et al. Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells. The Journal of Clinical Investigation. 123: 3876-88. PMID 23979164 DOI: 10.1172/Jci68557 |
0.521 |
|
| 2013 |
Rhyasen GW, Bolanos L, Fang J, Jerez A, Wunderlich M, Rigolino C, Mathews L, Ferrer M, Southall N, Guha R, Keller J, Thomas C, Beverly LJ, Cortelezzi A, Oliva EN, ... ... Mulloy JC, et al. Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome. Cancer Cell. 24: 90-104. PMID 23845443 DOI: 10.1016/J.Ccr.2013.05.006 |
0.453 |
|
| 2013 |
Huang H, Jiang X, Li Z, Li Y, Song CX, He C, Sun M, Chen P, Gurbuxani S, Wang J, Hong GM, Elkahloun AG, Arnovitz S, Wang J, Szulwach K, ... ... Mulloy JC, et al. TET1 plays an essential oncogenic role in MLL-rearranged leukemia. Proceedings of the National Academy of Sciences of the United States of America. 110: 11994-9. PMID 23818607 DOI: 10.1073/Pnas.1310656110 |
0.445 |
|
| 2013 |
Chen P, Price C, Li Z, Li Y, Cao D, Wiley A, He C, Gurbuxani S, Kunjamma RB, Huang H, Jiang X, Arnovitz S, Xu M, Hong GM, Elkahloun AG, ... ... Mulloy JC, et al. miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia. Proceedings of the National Academy of Sciences of the United States of America. 110: 11511-6. PMID 23798388 DOI: 10.1073/Pnas.1310144110 |
0.334 |
|
| 2013 |
Araten DJ, Krejci O, Ditata K, Wunderlich M, Sanders KJ, Zamechek L, Mulloy JC. The rate of spontaneous mutations in human myeloid cells. Mutation Research. 749: 49-57. PMID 23748046 DOI: 10.1016/J.Mrfmmm.2013.05.004 |
0.381 |
|
| 2013 |
Bell-Horwath TR, Vadukoot AK, Thowfeik FS, Li G, Wunderlich M, Mulloy JC, Merino EJ. Novel ROS-activated agents utilize a tethered amine to selectively target acute myeloid leukemia. Bioorganic & Medicinal Chemistry Letters. 23: 2951-4. PMID 23578690 DOI: 10.1016/J.Bmcl.2013.03.048 |
0.445 |
|
| 2013 |
Wunderlich M, Mizukawa B, Chou FS, Sexton C, Shrestha M, Saunthararajah Y, Mulloy JC. AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model. Blood. 121: e90-7. PMID 23349390 DOI: 10.1182/Blood-2012-10-464677 |
0.738 |
|
| 2013 |
Goyama S, Mulloy JC. Making healthy stem cells: the new role of TPO. Cell Stem Cell. 12: 8-9. PMID 23290133 DOI: 10.1016/J.Stem.2012.12.008 |
0.428 |
|
| 2013 |
Fang J, Barker B, Bolanos L, Liu X, Jerez A, Makishima H, Rao DS, Mulloy JC, Maciejewski JP, Cancelas JA, Starczynowski DT. SQSTM1/p62 Is a Necessary Cofactor In MDS/AML With Deletion Of Mir-146a Blood. 122: 747-747. DOI: 10.1182/Blood.V122.21.747.747 |
0.369 |
|
| 2013 |
Agerstam H, Askmyr M, Hansen N, Rissler M, Juliusson G, Richter J, Wunderlich M, Järås M, Mulloy JC, Fioretos T. Strong Therapeutic Effect Of Anti-IL1RAP Immunotherapy In a Xenograft Model Of Acute Myeloid Leukemia Blood. 122: 3954-3954. DOI: 10.1182/Blood.V122.21.3954.3954 |
0.47 |
|
| 2013 |
Konopleva M, Benito JM, Harutyunyan KG, Marzo I, Debose L, Gonzalo O, Zhou P, Jacamo R, Park E, Muschen M, Mulloy JC, Bendall LJ, Zweidler-McKay PA, Coombes KR, Qiu Y, et al. Acute Lymphoblastic Leukemia Is a Bcl-2 Dependent Disease: Proteomic Profiling and Pre-Clinical Efficacy Of a Selective Bcl-2 Antagonist ABT-199 Blood. 122: 3919-3919. DOI: 10.1182/Blood.V122.21.3919.3919 |
0.467 |
|
| 2013 |
Wunderlich M, Sexton C, Mizukawa B, Mulloy JC. NSGS Mice Develop a Progressive, Myeloid Cell Dependent Aplastic Anemia and Bone Marrow Failure Upon Engraftment With Human Umbilical Cord Blood CD34+ Cells Blood. 122: 3716-3716. DOI: 10.1182/Blood.V122.21.3716.3716 |
0.492 |
|
| 2013 |
Mizukawa B, O'Brien E, Liu W, Ridsdale DM, Wunderlich M, Zheng Y, Mulloy JC. Maintenance Of Bone Marrow Residency and Self-Renewal Of Leukemic Stem Cells By Cdc42 Gtpase Blood. 122: 2889-2889. DOI: 10.1182/Blood.V122.21.2889.2889 |
0.541 |
|
| 2013 |
Wunderlich M, Brooks R, Rhyasen G, Mulloy JC. CD3 Antibody Treatment Prevents Gvhd and Allows For Rapid, Long Term, Multilineage Engraftment Of Unfractionated UCB Into Immunodeficient Mice Blood. 122: 2018-2018. DOI: 10.1182/Blood.V122.21.2018.2018 |
0.485 |
|
| 2012 |
Jiang X, Huang H, Li Z, He C, Li Y, Chen P, Gurbuxani S, Arnovitz S, Hong GM, Price C, Ren H, Kunjamma RB, Neilly MB, Salat J, Wunderlich M, ... ... Mulloy JC, et al. MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia. Proceedings of the National Academy of Sciences of the United States of America. 109: 19397-402. PMID 23132946 DOI: 10.1073/Pnas.1217519109 |
0.38 |
|
| 2012 |
Zhang Y, Yan X, Sashida G, Zhao X, Rao Y, Goyama S, Whitman SP, Zorko N, Bernot K, Conway RM, Witte D, Wang QF, Tenen DG, Xiao Z, Marcucci G, ... Mulloy JC, et al. Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cells. Blood. 120: 1118-29. PMID 22740449 DOI: 10.1182/Blood-2012-02-412379 |
0.488 |
|
| 2012 |
Fang J, Rhyasen G, Bolanos L, Rasch C, Varney M, Wunderlich M, Goyama S, Jansen G, Cloos J, Rigolino C, Cortelezzi A, Mulloy JC, Oliva EN, Cuzzola M, Starczynowski DT. Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1. Blood. 120: 858-67. PMID 22685174 DOI: 10.1182/Blood-2012-02-407999 |
0.51 |
|
| 2012 |
Yoshimi M, Goyama S, Kawazu M, Nakagawa M, Ichikawa M, Imai Y, Kumano K, Asai T, Mulloy JC, Kraft AS, Takahashi T, Shirafuji N, Kurokawa M. Multiple phosphorylation sites are important for RUNX1 activity in early hematopoiesis and T-cell differentiation. European Journal of Immunology. 42: 1044-50. PMID 22531928 DOI: 10.1002/Eji.201040746 |
0.346 |
|
| 2012 |
Li Z, Huang H, Chen P, He M, Li Y, Arnovitz S, Jiang X, He C, Hyjek E, Zhang J, Zhang Z, Elkahloun A, Cao D, Shen C, Wunderlich M, ... ... Mulloy JC, et al. miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia. Nature Communications. 3: 688. PMID 22353710 DOI: 10.1038/Ncomms1681 |
0.31 |
|
| 2012 |
Chou FS, Griesinger A, Wunderlich M, Lin S, Link KA, Shrestha M, Goyama S, Mizukawa B, Shen S, Marcucci G, Mulloy JC. The thrombopoietin/MPL/Bcl-xL pathway is essential for survival and self-renewal in human preleukemia induced by AML1-ETO. Blood. 120: 709-19. PMID 22337712 DOI: 10.1182/Blood-2012-01-403212 |
0.72 |
|
| 2012 |
Maiques-Diaz A, Chou FS, Wunderlich M, Gómez-López G, Jacinto FV, Rodriguez-Perales S, Larrayoz MJ, Calasanz MJ, Mulloy JC, Cigudosa JC, Alvarez S. Chromatin modifications induced by the AML1-ETO fusion protein reversibly silence its genomic targets through AML1 and Sp1 binding motifs. Leukemia. 26: 1329-37. PMID 22289984 DOI: 10.1182/Blood.V118.21.2422.2422 |
0.685 |
|
| 2012 |
Negrotto S, Ng KP, Jankowska AM, Bodo J, Gopalan B, Guinta K, Mulloy JC, Hsi E, MacIejewski J, Saunthararajah Y. CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors Leukemia. 26: 244-254. PMID 21836612 DOI: 10.1038/Leu.2011.207 |
0.444 |
|
| 2012 |
Wunderlich M, Shrestha M, Kang L, Law E, Jankovic V, Zhang X, Herzberg U, Abbot S, Hariri R, Mulloy JC. Stroma-Free Ex Vivo Expanded, CD34+ Cord Blood-Derived NK Cells Retain Lytic Activity After Long-Term Engraftment in NSGS Mice Blood. 120: 580-580. DOI: 10.1182/Blood.V120.21.580.580 |
0.477 |
|
| 2012 |
Desmond RG, Bat T, Kamenyeva O, Mizukawa B, Mulloy JC, Larochelle A, Dunbar CE. Leukemic and Hematopoietic Stem Cells Compete for the Same Functional Marrow Niche in a MLL-AF9 Murine Leukemia Model Blood. 120: 4897-4897. DOI: 10.1182/Blood.V120.21.4897.4897 |
0.5 |
|
| 2012 |
Rhyasen G, Wunderlich M, Mulloy JC, Starczynowski DT. Development and Characterization of a Novel Human Xenograft Model Using an MDS Patient-Derived Cell Line Blood. 120: 3814-3814. DOI: 10.1182/Blood.V120.21.3814.3814 |
0.522 |
|
| 2012 |
Mehta PA, Wunderlich M, Smolarek T, Davies SM, Zimmerman S, Filipovich AH, Broxson EH, Cancelas JA, Mulloy JC. Prenatal Origin of Monosomy 7 in Very Young Children. Blood. 120: 2557-2557. DOI: 10.1182/Blood.V120.21.2557.2557 |
0.347 |
|
| 2012 |
Roychoudhury J, Clark JP, Link KA, Huang G, Mulloy JC, Kumar A. Genetic Models Demonstrate a Requirement of MEIS1 in Survival of MLL-AF9 Leukemia Blood. 120: 120-120. DOI: 10.1182/Blood.V120.21.120.120 |
0.519 |
|
| 2011 |
Mizukawa B, Wei J, Shrestha M, Wunderlich M, Chou FS, Griesinger A, Harris CE, Kumar AR, Zheng Y, Williams DA, Mulloy JC. Inhibition of Rac GTPase signaling and downstream prosurvival Bcl-2 proteins as combination targeted therapy in MLL-AF9 leukemia. Blood. 118: 5235-45. PMID 21940819 DOI: 10.1182/Blood-2011-04-351817 |
0.725 |
|
| 2011 |
Sipes NS, Feng Y, Guo F, Lee HO, Chou FS, Cheng J, Mulloy J, Zheng Y. Cdc42 regulates extracellular matrix remodeling in three dimensions. The Journal of Biological Chemistry. 286: 36469-77. PMID 21880728 DOI: 10.1074/Jbc.M111.283176 |
0.663 |
|
| 2011 |
Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, Taylor MJ, Johns C, Chicas A, Mulloy JC, Kogan SC, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 478: 524-8. PMID 21814200 DOI: 10.1038/Nature10334 |
0.438 |
|
| 2011 |
Ng KP, Ebrahem Q, Negrotto S, Mahfouz RZ, Link KA, Hu Z, Gu X, Advani A, Kalaycio M, Sobecks R, Sekeres M, Copelan E, Radivoyevitch T, MacIejewski J, Mulloy JC, et al. P53 Independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia Leukemia. 25: 1739-1750. PMID 21701495 DOI: 10.1038/Leu.2011.159 |
0.479 |
|
| 2011 |
Goyama S, Mulloy JC. Molecular pathogenesis of core binding factor leukemia: current knowledge and future prospects. International Journal of Hematology. 94: 126-33. PMID 21537931 DOI: 10.1007/S12185-011-0858-Z |
0.381 |
|
| 2011 |
Chou FS, Mulloy JC. The thrombopoietin/MPL pathway in hematopoiesis and leukemogenesis. Journal of Cellular Biochemistry. 112: 1491-8. PMID 21360575 DOI: 10.1002/Jcb.23089 |
0.704 |
|
| 2011 |
Chou FS, Wunderlich M, Griesinger A, Mulloy JC. N-Ras(G12D) induces features of stepwise transformation in preleukemic human umbilical cord blood cultures expressing the AML1-ETO fusion gene. Blood. 117: 2237-40. PMID 21200020 DOI: 10.1182/Blood-2010-01-264119 |
0.692 |
|
| 2011 |
Shen S, Zheng Y, Mulloy JC. The Leukemia-Associated Rho Guanine Nucleotide Exchange Factor (LARG) Is Essential for Survival and Proliferation of AML1-ETO Associated AML Cells Blood. 118: 923-923. DOI: 10.1182/Blood.V118.21.923.923 |
0.567 |
|
| 2011 |
Goyama S, Schibler J, Rao Y, Wunderlich M, Link KA, Huang G, Mulloy JC. Pro-Survival Role of RUNX1 in Acute Myeloid Leukemia with Common Fusion Proteins Blood. 118: 870-870. DOI: 10.1182/Blood.V118.21.870.870 |
0.587 |
|
| 2011 |
Zhang Y, Yan X, Sashida G, Zhao X, Rao Y, Goyama S, Whitman SP, Zorko N, Bernot KM, Witte D, Wang Q, Tenen DG, Xiao Z, Marcucci G, Mulloy JC, et al. MLL-PTD Causes Hypomorph Condition of CBF Complex (RUNX1/CBFβ) and Predisposes the Abnormal Hematopoietic Stem and Progenitor Cells (HSPCs) to Clonal Expansion Blood. 118: 2801-2801. DOI: 10.1182/Blood.V118.21.2801.2801 |
0.479 |
|
| 2011 |
Goyama S, Schibler J, Mulloy JC. C-CBL Inactivation Promotes Cytokine-Driven Growth of Human CD34+ Cells and AML1-ETO Expressing Cells Blood. 118: 2464-2464. DOI: 10.1182/Blood.V118.21.2464.2464 |
0.464 |
|
| 2011 |
Mizukawa B, Shrestha M, Wunderlich M, Chou F, Griesinger A, Kumar A, Zheng Y, Williams DA, Mulloy JC. Rac GTPase Survival Signaling Through Anti-Apoptotic Bcl-2 Proteins Reveals a Target for Combination Therapy in MLL-AF9 Acute Myeloid Leukemia Blood. 118: 1536-1536. DOI: 10.1182/Blood.V118.21.1536.1536 |
0.768 |
|
| 2011 |
Link KA, Lin S, Komurov K, Wunderlich M, Mulloy JC. Oncogene Dosage Is a Major Determinant of Leukemogenic Transformation by AE9a Blood. 118: 1358-1358. DOI: 10.1182/Blood.V118.21.1358.1358 |
0.571 |
|
| 2010 |
Alvarez S, Suela J, Valencia A, Fernández A, Wunderlich M, Agirre X, Prósper F, Martín-Subero JI, Maiques A, Acquadro F, Rodriguez Perales S, Calasanz MJ, Roman-Gómez J, Siebert R, Mulloy JC, et al. DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia. Plos One. 5: e12197. PMID 20808941 DOI: 10.1371/Journal.Pone.0012197 |
0.313 |
|
| 2010 |
Wunderlich M, Chou FS, Link KA, Mizukawa B, Perry RL, Carroll M, Mulloy JC. AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. Leukemia. 24: 1785-8. PMID 20686503 DOI: 10.1038/leu.2010.158 |
0.643 |
|
| 2010 |
Kamikubo Y, Zhao L, Wunderlich M, Corpora T, Hyde RK, Paul TA, Kundu M, Garrett L, Compton S, Huang G, Wolff L, Ito Y, Bushweller J, Mulloy JC, Liu PP. Accelerated leukemogenesis by truncated CBF beta-SMMHC defective in high-affinity binding with RUNX1. Cancer Cell. 17: 455-68. PMID 20478528 DOI: 10.1016/J.Ccr.2010.03.022 |
0.353 |
|
| 2010 |
Mulloy JC. Peripheral T cell lymphoma: new model + new insight. The Journal of Experimental Medicine. 207: 911-3. PMID 20439538 DOI: 10.1084/Jem.20100608 |
0.381 |
|
| 2010 |
Mi S, Li Z, Chen P, He C, Cao D, Elkahloun A, Lu J, Pelloso LA, Wunderlich M, Huang H, Luo RT, Sun M, He M, Neilly MB, Zeleznik-Le NJ, ... ... Mulloy JC, et al. Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemia. Proceedings of the National Academy of Sciences of the United States of America. 107: 3710-5. PMID 20133587 DOI: 10.1073/Pnas.0914900107 |
0.324 |
|
| 2010 |
Mulloy JC, Cancelas JA, Filippi MD, Kalfa TA, Guo F, Zheng Y. Rho GTPases in hematopoiesis and hemopathies. Blood. 115: 936-47. PMID 19965643 DOI: 10.1182/Blood-2009-09-198127 |
0.495 |
|
| 2010 |
Link KA, Chou FS, Mulloy JC. Core binding factor at the crossroads: determining the fate of the HSC. Journal of Cellular Physiology. 222: 50-6. PMID 19813271 DOI: 10.1002/Jcp.21950 |
0.701 |
|
| 2010 |
Wunderlich M, Presicce P, Chou F, Chougnet C, Aliberti J, Mulloy JC. Enhanced Myeloid and T Cell Development and Improved Functionality of Cord Blood Xenografts In the NSGS Mouse. Blood. 116: 3729-3729. DOI: 10.1182/Blood.V116.21.3729.3729 |
0.738 |
|
| 2010 |
Link KA, Wunderlich M, Huang G, Mulloy JC. Gene Dosage Is a Critical Parameter In a Structure/Function Analysis of the AML1-ETO Oncogene In Human and Murine Stem and Progenitor Cells. Blood. 116: 3644-3644. DOI: 10.1182/Blood.V116.21.3644.3644 |
0.513 |
|
| 2010 |
Ng KP, Ebrahem Q, Negrotto S, Mahfouz R, Link K, Hu Z, Gu X, Advani A, Kalaycio M, Sekeres MA, Copelan EA, Maciejewski JP, Mulloy JC, Saunthararajah Y. Effective and Non-Cytotoxic p53 Independent Epigenetic-Differentiation Therapy In Xeno-Transplant Models of Human Acute Myeloid Leukemia Blood. 116: 3309-3309. DOI: 10.1182/Blood.V116.21.3309.3309 |
0.529 |
|
| 2010 |
Wunderlich M, Chou F, Shrestha M, Mizukawa B, Mulloy JC. Adaptation of a Xenograft AML Model to Evaluate Chemotherapeutic Efficacy In Vivo Blood. 116: 3304-3304. DOI: 10.1182/Blood.V116.21.3304.3304 |
0.736 |
|
| 2009 |
Wunderlich M, Mulloy JC. Model systems for examining effects of leukemia-associated oncogenes in primary human CD34+ cells via retroviral transduction. Methods in Molecular Biology (Clifton, N.J.). 538: 263-85. PMID 19277588 DOI: 10.1007/978-1-59745-418-6_13 |
0.487 |
|
| 2009 |
Bosco EE, Mulloy JC, Zheng Y. Rac1 GTPase: A "Rac" of all trades Cellular and Molecular Life Sciences. 66: 370-374. PMID 19151919 DOI: 10.1007/S00018-008-8552-X |
0.392 |
|
| 2009 |
Chou F, Wunderlich M, Mulloy JC. Bcl-Xl Mitigates p53 Activity in AML1-ETO-Expressing Human Hematopoietic Cells. Blood. 114: 387-387. DOI: 10.1182/Blood.V114.22.387.387 |
0.756 |
|
| 2009 |
Wunderlich M, Chou F, Mizukawa B, Link KA, Mulloy JC. A New Immunodeficient Mouse Strain, NOD/SCID IL2Rγ−/− SGM3, Promotes Enhanced Human Hematopoietic Cell Xenografts with a Robust T Cell Component. Blood. 114: 3524-3524. DOI: 10.1182/Blood.V114.22.3524.3524 |
0.736 |
|
| 2009 |
Wunderlich M, Link KA, Chou F, Mulloy JC. Constitutive Activation of Rac GTPases Is Induced by Cooperating Mutations in a Human Model of MLL-AF9 Leukemia. Blood. 114: 2959-2959. DOI: 10.1182/Blood.V114.22.2959.2959 |
0.761 |
|
| 2009 |
Alvarez S, Suela J, Valencia A, Fernandez A, Wunderlich M, Agirre X, Prosper F, Martin-Subero JI, Maiques A, Acquadro F, Rodriguez-Perales S, Calasanz MJ, Roman-Gomez J, Siebert R, Mulloy JC, et al. Epigenomic Analysis of Acute Myeloid Leukemia Identifies Specific Patterns and Markes with Clinical and Biological Relevance. Blood. 114: 2394-2394. DOI: 10.1182/Blood.V114.22.2394.2394 |
0.396 |
|
| 2009 |
Ng KP, Negrotto S, Hu Z, Link KA, Saraf SL, Advani A, Sekeres MA, Maciejewski JP, Mulloy JC, Saunthararajah Y. Non-p53 Dependent, Leukemia Initiating-Cell Selective, Therapy. Blood. 114: 2077-2077. DOI: 10.1182/Blood.V114.22.2077.2077 |
0.549 |
|
| 2009 |
Mizukawa B, Wei J, Wunderlich M, Chou F, Zheng Y, Williams DA, Mulloy JC. Bcl-XL Is a Critical Mediator of Rac Signaling in MLL-AF9-Induced Acute Myeloid Leukemia. Blood. 114: 1971-1971. DOI: 10.1182/Blood.V114.22.1971.1971 |
0.76 |
|
| 2009 |
Chou F, Wunderlich M, Mulloy JC. Thrombopoietin/Bcl-Xl Signaling Is Essential for the Self-Renewal Phenotypes of AML1-ETO Expressing Human Hematopoietic Cells. Blood. 114: 1424-1424. DOI: 10.1182/Blood.V114.22.1424.1424 |
0.773 |
|
| 2009 |
Liu W, Mizukawa B, Wunderlich M, Johnson JF, Mulloy JC, Zheng Y. A Novel Method of Mobilizing Leukemia Initiating Cells by a Small Molecule Cdc42 Activity-Specific Inhibitor (CASIN) for Acute Myeloid Leukemia Therapy. Blood. 114: 13-13. DOI: 10.1182/Blood.V114.22.13.13 |
0.548 |
|
| 2009 |
Negrotto S, Hu Z, Link KA, Ng KP, Bodo J, Duong H, Schade A, Hsi E, Lindner D, Maciejewski J, Mulloy J, Saunthararajah Y. A Therapeutically Relevant Difference in Leukemia and Normal Stem Cell Self Renewal Nature Precedings. DOI: 10.1038/Npre.2009.3044.1 |
0.464 |
|
| 2008 |
Mulloy JC, Wunderlich M, Zheng Y, Wei J. Transforming human blood stem and progenitor cells: a new way forward in leukemia modeling. Cell Cycle (Georgetown, Tex.). 7: 3314-9. PMID 18948748 DOI: 10.4161/Cc.7.21.6951 |
0.513 |
|
| 2008 |
Wei J, Wunderlich M, Fox C, Alvarez S, Cigudosa JC, Wilhelm JS, Zheng Y, Cancelas JA, Gu Y, Jansen M, Dimartino JF, Mulloy JC. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. Cancer Cell. 13: 483-95. PMID 18538732 DOI: 10.1016/J.Ccr.2008.04.020 |
0.552 |
|
| 2008 |
Krejci O, Wunderlich M, Geiger H, Chou FS, Schleimer D, Jansen M, Andreassen PR, Mulloy JC. p53 signaling in response to increased DNA damage sensitizes AML1-ETO cells to stress-induced death. Blood. 111: 2190-9. PMID 17975013 DOI: 10.1182/Blood-2007-06-093682 |
0.697 |
|
| 2008 |
Chou F, Wunderlich M, Mulloy JC. Bcl-2 Family Dysregulation in AML1-ETO-Expressing Human Hematopoietic Cells Blood. 112: 5330-5330. DOI: 10.1182/Blood.V112.11.5330.5330 |
0.747 |
|
| 2008 |
Wei J, Wunderlich M, Harris C, Mizukawa B, Zheng Y, Williams DA, Mulloy JC. Rac GTPases Are Required for MLL-AF9-Induced Mixed Lineage Leukemia. Blood. 112: 3368-3368. DOI: 10.1182/Blood.V112.11.3368.3368 |
0.586 |
|
| 2008 |
Negrotto S, Hu Z, Link KA, Duong H, Schade AE, Maciejewski JP, Mulloy JC, Saunthararajah Y. Differentiation-Chronology Specific Function of DNMT1 and Selective Anti-Leukemia Stem-Cell Therapy Blood. 112: 201-201. DOI: 10.1182/Blood.V112.11.201.201 |
0.487 |
|
| 2007 |
Wei J, Mark W, Fox C, DiMartino JF, Mulloy JC. Environmental Factors Determine Lineage Fate in a Human Model of MLL-AF9 Leukemia. Blood. 110: 3374-3374. DOI: 10.1182/Blood.V110.11.3374.3374 |
0.503 |
|
| 2007 |
Araten DJ, Mulloy JC, Krejci O, DiTata K. A Novel Measurement of the Rate of Spontaneous Mutations in Human Myeloid Cells. Blood. 110: 1823-1823. DOI: 10.1182/Blood.V110.11.1823.1823 |
0.421 |
|
| 2006 |
Wunderlich M, Krejci O, Wei J, Mulloy JC. Human CD34+ cells expressing the inv(16) fusion protein exhibit a myelomonocytic phenotype with greatly enhanced proliferative ability. Blood. 108: 1690-7. PMID 16670269 DOI: 10.1182/Blood-2005-12-012773 |
0.537 |
|
| 2006 |
Wei J, Wunderlich M, Krejci O, Alvarez S, Cigudosa J, Mulloy JC. Immortalization of Human HSPC by a Self-Renewal Signal Coupled with Telomere Maintenance. Blood. 108: 2547-2547. DOI: 10.1182/Blood.V108.11.2547.2547 |
0.541 |
|
| 2006 |
Mulloy JC, Wei J, Rettig C, Wunderlich M, Alvarez S, Cigudosa J, Jansen M, DiMartino JF. Leukemic Transformation of Primary Human CD34+ Progenitor Cells by MLL-AF9 Recapitulates the Phenotype and Gene Expression Profile of MLL Rearranged AML. Blood. 108: 2210-2210. DOI: 10.1182/Blood.V108.11.2210.2210 |
0.532 |
|
| 2006 |
Krejci O, Wunderlich M, Wei J, Andreassen PR, Lu TX, Mulloy JC. AML1-ETO Inhibits DNA Repair Pathways and Promotes the Accumulation of DNA Damage and the Activation of p53. Blood. 108: 1412-1412. DOI: 10.1182/Blood.V108.11.1412.1412 |
0.492 |
|
| 2005 |
Mulloy JC, Jankovic V, Wunderlich M, Delwel R, Cammenga J, Krejci O, Zhao H, Valk PJ, Lowenberg B, Nimer SD. AML1-ETO fusion protein up-regulates TRKA mRNA expression in human CD34+ cells, allowing nerve growth factor-induced expansion. Proceedings of the National Academy of Sciences of the United States of America. 102: 4016-21. PMID 15731354 DOI: 10.1073/Pnas.0404701102 |
0.504 |
|
| 2005 |
Wei J, Wunderlich M, Mulloy JC. Telomerase Promotes the Self-Renewal of Human Hematopoietic Progenitor Cells but Does Not Maintain Telomere Length. Blood. 106: 647-647. DOI: 10.1182/Blood.V106.11.647.647 |
0.527 |
|
| 2005 |
DiMartino JF, Rettig C, Wunderlich M, Mulloy JC. Retroviral Mediated Transfer of MLL Fusion Genes into Human CD34+ Cord Blood Cells Supports the Establishment of Long-Term Myeloid Cultures with Growth Rates, Immunophenotypic and Transcriptional Features Distinct from Those of AML1-ETO Transduced Cultures. Blood. 106: 1610-1610. DOI: 10.1182/Blood.V106.11.1610.1610 |
0.471 |
|
| 2005 |
Wunderlich M, Krejci O, Wei J, Lu TX, Mulloy JC. Human CD34+ Cells Expressing CBFβ-MYH11 Exhibit a Myelomonocytic Phenotype with Greatly Enhanced Proliferative Ability. Blood. 106: 1379-1379. DOI: 10.1182/Blood.V106.11.1379.1379 |
0.554 |
|
| 2003 |
Mulloy JC, Cammenga J, Berguido FJ, Wu K, Zhou P, Comenzo RL, Jhanwar S, Moore MA, Nimer SD. Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element. Blood. 102: 4369-76. PMID 12946995 DOI: 10.1182/Blood-2003-05-1762 |
0.501 |
|
| 2003 |
Cammenga J, Mulloy JC, Berguido FJ, MacGrogan D, Viale A, Nimer SD. Induction of C/EBPalpha activity alters gene expression and differentiation of human CD34+ cells. Blood. 101: 2206-14. PMID 12406909 DOI: 10.1182/blood-2002-05-1546 |
0.375 |
|
| 2002 |
Mulloy JC, Cammenga J, MacKenzie KL, Berguido FJ, Moore MA, Nimer SD. The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. Blood. 99: 15-23. PMID 11756147 DOI: 10.1182/Blood.V99.1.15 |
0.547 |
|
| 2001 |
Nicot C, Mulloy JC, Ferrari MG, Johnson JM, Fu K, Fukumoto R, Trovato R, Fullen J, Leonard WJ, Franchini G. HTLV-1 p12I protein enhances STAT5 activation and decreases the interleukin-2 requirement for proliferation of primary human peripheral blood mononuclear cells Blood. 98: 823-829. PMID 11468184 DOI: 10.1182/Blood.V98.3.823 |
0.439 |
|
| 2001 |
Johnson JM, Nicot C, Fullen J, Ciminale V, Casareto L, Mulloy JC, Jacobson S, Franchini G. Free major histocompatibility complex class I heavy chain is preferentially targeted for degradation by human T-cell leukemia/lymphotropic virus type 1 p12I protein Journal of Virology. 75: 6086-6094. PMID 11390610 DOI: 10.1128/Jvi.75.13.6086-6094.2001 |
0.366 |
|
| 1999 |
Ekholm D, Mulloy JC, Gao G, Degerman E, Franchini G, Manganiello VC. Cyclic nucleotide phosphodiesterases (PDE) 3 and 4 in normal, malignant, and HTLV-I transformed human lymphocytes Biochemical Pharmacology. 58: 935-950. PMID 10509746 DOI: 10.1016/S0006-2952(99)00188-4 |
0.38 |
|
| 1999 |
Trovato R, Mulloy JC, Johnson JM, Takemoto S, De Oliveira MP, Franchini G. A lysine-to-arginine change found in natural alleles of the human T- cell lymphotropic/leukemia virus type 1 p12(I) protein greatly influences its stability Journal of Virology. 73: 6460-6467. PMID 10400740 DOI: 10.1128/Jvi.73.8.6460-6467.1999 |
0.361 |
|
| 1999 |
Takemoto S, Casareto L, Mulloy JC, White JD, Waldmann T, Franchini G. ABNORMAL ACTIVATION OF STAT5 PROTEINS UPON IL-4 TRIGGERING OF ATLL CELLS Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 20: A45. DOI: 10.1097/00042560-199904010-00166 |
0.334 |
|
| 1998 |
Mulloy JC, Kislyakova T, Cereseto A, Casareto L, Lomonico A, Fullen J, Lorenzi MV, Cara A, Nicot C, Giam CZ, Franchini G. Human T-cell lymphotropic/leukemia virus type 1 tax abrogates p53- induced cell cycle arrest and apoptosis through its CREB/ATF functional domain Journal of Virology. 72: 8852-8860. PMID 9765430 |
0.319 |
|
| 1998 |
Mulloy JC, Migone TS, Ross TM, Ton N, Green PL, Leonard WJ, Franchini G. Human and simian T-cell leukemia viruses type 2 (HTLV-2 and STLV- 2(pan-p)) transform T cells independently of Jak/STAT activation Journal of Virology. 72: 4408-4412. PMID 9557732 DOI: 10.1128/Jvi.72.5.4408-4412.1998 |
0.407 |
|
| 1997 |
Takemoto S, Mulloy JC, Cereseto A, Migone TS, Patel BKR, Matsuoka M, Yamaguchi K, Takatsuki K, Kamihira S, White JD, Leonard WJ, Waldmann T, Franchini G. Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins Proceedings of the National Academy of Sciences of the United States of America. 94: 13897-13902. PMID 9391124 DOI: 10.1073/Pnas.94.25.13897 |
0.489 |
|
| 1996 |
Cereseto A, Mulloy JC, Franchini G. Insights on the pathogenicity of human T-lymphotropic/leukemia virus types I and II Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 13. PMID 8797707 DOI: 10.1097/00042560-199600001-00013 |
0.401 |
|
| 1996 |
Cereseto A, Diella F, Mulloy JC, Cara A, Michieli P, Grassmann R, Franchini G, Klotman ME. p53 Functional impairment and high p21(waf1/cip1) expression in human T- cell lymphotropic/leukemia virus type I - Transformed T cells Blood. 88: 1551-1560. PMID 8781409 |
0.326 |
|
| 1995 |
Koralnik IJ, Mulloy JC, Andresson T, Fullen J, Franchini G. Mapping of the intermolecular association of the human T cell leukaemia/lymphotropic virus type I p12(I) and the vacuolar H+-ATPase 16 kDa subunit protein Journal of General Virology. 76: 1909-1916. PMID 7636472 DOI: 10.1099/0022-1317-76-8-1909 |
0.334 |
|
| Show low-probability matches. |